NEW YORK (GenomeWeb News) — Twelve drug makers, including six top-10 pharma companies, signed up as “formation members” of what is being called the Severe Adverse Event Consortium, a far-reaching project to identify genetic biomarkers that might predict serious adverse events, according to a recent presentation made by its chairman.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.